Doheny Eye Institute

Organization Overview

Doheny Eye Institute is located in Los Angeles, CA. The organization was established in 1973. According to its NTEE Classification (G41) the organization is classified as: Eye Diseases, Blindness & Vision Impairments, under the broad grouping of Voluntary Health Associations & Medical Disciplines and related organizations. As of 06/2022, Doheny Eye Institute employed 153 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Doheny Eye Institute is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.

For the year ending 06/2022, Doheny Eye Institute generated $66.1m in total revenue. This organization has experienced exceptional growth, as over the past 7 years, it has increased revenue by an average of 16.9% each year . All expenses for the organization totaled $19.9m during the year ending 06/2022. You can explore the organizations financials more deeply in the financial statements section below.

Mission & Program ActivityExcerpts From the 990T Filing

TAX YEAR

2022

Describe the Organization's Mission:

Part 3 - Line 1

TO FURTHER THE CONSERVATION, IMPROVEMENT AND RESTORATION OF HUMAN EYESIGHT.

Describe the Organization's Program Activity:

THE MISSION OF THE DOHENY EYE INSTITUTE (DEI), TO FURTHER THE CONSERVATION, IMPROVEMENT AND RESTORATION OF HUMAN EYESIGHT, IS GUIDED BY THE FOLLOWING OBJECTIVES: 1. TO INCREASE KNOWLEDGE OF THE HUMAN EYE, ITS CONDITIONS AND DISEASES, THROUGH RESEARCH; 2. TO TRANSMIT THIS KNOWLEDGE THROUGH EDUCATION, TRAINING, AND COMMUNITY SERVICE; AND 3. TO FACILITATE THE APPLICATION OF ITS RESEARCH TO IMPROVE PATIENT CARE AND FOSTER FURTHER RESEARCH. RESEARCH ACTIVITIES FOR THE PERIOD AND SELECTED FOR LONG-TERM FOCUS INCLUDE: RETINAL AND MACULAR DEGENERATION RESEARCH THROUGH THE STUDY OF RETINAL PIGMENT EPITHELIUM AND THE USE OF ADVANCED RETINAL IMAGING IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD) AND IMAGE ANALYSIS USING ARTIFICIAL INTELLEGENCE; MOLECULAR GENETICS OF INHERITED DISEASE OF THE RETINA AND GENE THERAPY FOR RETINAL DISORDERS; INVESTIGATIONS OF RETINAL VASCULAR STIFFNESS AS A POTENTIAL CAUSATIVE FACTOR IN DIABETIC RETINOPATHY AND AMD; RESEARCH FOCUSED ON DEFINING THE MOLECULAR DETAILS LINKING MITOCHONDRIAL DYSFUNCTION AND ALTERED SIGNALING BETWEEN RETINAL NEURONS. ON DECEMBER 18, 2013, THE DOHENY EYE INSTITUTE EXECUTED AN AGREEMENT WITH THE UNIVERSITY OF CALIFORNIA AT LOS ANGELES (UCLA) FOR A 99 YEAR AFFILIATION. THE PURPOSE OF THIS AFFILIATION IS TO CARRY OUT THE INSTITUTE'S MISSION -- TO FURTHER THE CONSERVATION, IMPROVEMENT, AND RESTORATION OF HUMAN EYESIGHT -- THROUGH RESEARCH, EDUCATION, AND CLINICAL CARE (CLINICAL CARE IS PROVIDED DIRECTLY BY UCLA). BOTH THE INSTITUTE AND UCLA-STEIN EYE INSTITUTE ARE DEDICATED TO PROVIDING THE PUBLIC WITH THE HIGHEST QUALITY OF OPHTHALMIC CARE AND THE MOST INNOVATIVE AND STRATEGIC RESEARCH FOR THE IMPROVEMENT OF HUMAN EYESIGHT. IN NOV. 2021 DOHENY EYE INSTITUTE (DEI) MOVED TO ITS NEW LOCATION - 150 ORANGE GROVE BLVD IN PASADENA, CA. NEW AREAS OF RESEARCH DEI IS STUDYING THE MECHANISMS RESPONSIBLE FOR DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION (AMD), THE NUMBER ONE CAUSE OF BLINDNESS AMONG INDIVIDUALS OVER 60 YEARS OLD IN THE USA. THE RISK OF DEVELOPING AMD IS SIGNIFICANTLY INCREASED WHEN SPECIFIC GENES ARE MUTATED. ONE NEW STUDY IS FOCUSED ON STUDYING THE RETINAL CELLS IN THE POPULATION OF PATIENTS HARBORING A SPECIFIC MUTATION IN A GENE INVOLVED IN THE IMMUNE SYSTEM. A SECOND STUDY IS FOCUSED ON A SECOND GENE OF UNKNOWN FUNCTION BUT WITH HIGH IMPACT ON AMD. THE RESEARCHERS ARE STUDYING RETINAL CELLS GENERATED FROM AMD PATIENTS THAT HAVE THESE GENETIC DEFECTS. INFORMATION FROM THESE TWO STUDIES IS CRITICAL FOR DEVELOPMENT OF NEW THERAPIES FOR AMD THAT TARGET WHAT IS CAUSING THE DISEASE. IN OTHER STUDIES, DEI SCIENTISTS HAVE BEEN INVOLVED IN DEVELOPING NEW AND FASTER WAYS TO INTERPRET RETINAL IMAGES IN HUMAN PATIENTS USING ARTIFICIAL INTELLIGENCE (AI). IN ONE STUDY, AI-BASED APPROACHES FOR AUTOMATED INTERPRETATION OF IMAGES FROM PATIENTS WITH STARGARDT ATROPHY INCORPORATES INFORMATION FROM MULTIPLE IMAGING MODALITIES. ADDITIONALLY, BY FOLLOWING PATIENT IMAGES OVER TIME, AN AI-BASED AUTOMATED ALGORITHM IS BEING DEVELOPED TO PREDICT NEW STARGARDT ATROPHY OR PROGRESSION OVER TIME. DEI HAS DEVELOPED CUTTING EDGE IMAGING TECHNOLOGY, INCLUDING A NOVEL ADAPTIVE OPTICS NEAR-CONFOCAL OPHTHALMOSCOPE (AONCO) THAT ENABLES PRECISE EVALUATION OF THE DYNAMIC MOVEMENT OF ERYTHROCYTES WITHIN RETINAL CAPILLARIES, REFERRED TO AS "HIGHER-ORDER DYNAMICS". BY MONITORING ERYTHROCYTE VELOCITY WITHIN A CARDIAC CYCLE, THEY WILL VALIDATE THAT HIGHER ORDER HEMODYNAMICS IN RETINAL CAPILLARIES RESEMBLE THOSE CREATED FOR ASSESSING THE ARTERIAL STIFFNESS IN THE MACROVASCULAR SYSTEM. THIS WORK IS IMPORTANT BECAUSE WE WILL GAIN A BETTER UNDERSTANDING OF THE HIGHER-ORDER HEMODYNAMICS IN NORMAL HUMAN RETINAL CAPILLARIES AND DEVELOP NEW BIOMARKERS FOR DETECTING AGE- AND DISEASE-RELATED CHANGES IN THE RETINAL MICROCIRCULATION. DEI HAS ALSO DEVELOPED A PIONEERING ADAPTIVE OPTICS IMAGING INSTRUMENT THAT INTEGRATES SCANNING LASER OPHTHALMOSCOPY AND OPTICAL COHERENCE TOMOGRAPHY (AO-SLO-OCT). THIS INSTRUMENT CAN IMAGE THE RETINA WITH A 3-D SPATIAL RESOLUTION, ALLOWING FOR IN-VIVO ULTRASTRUCTURE ASSESSMENT OF RETICULAR PSEUDODRUSEN AND INDIVIDUAL PHOTORECEPTORS IN BOTH EN FACE AND CROSS-SECTIONAL PLANES. THE IMPORTANCE IS THAT THIS ADAPTIVE OPTICS IMAGING OVERCOMES THE LIMITATIONS PRESENTED BY OPTICAL DEFECTS IN LIVING EYES, ALLOWING FOR HIGH RESOLUTION IMAGES OF THE CHORIOCAPILLARIS IN THE STUDY OF VARIOUS CHORIORETINAL DISEASES, INCLUDING AGE-RELATED MACULAR DEGENERATION. ANOTHER IMAGING TECHNIQUE USED BY DEI SCIENTISTS IS THE USE OF CALCIUM IMAGING IN CONJUNCTION WITH CONFOCAL MICROSCOPY TO CHARACTERIZE THE EFFECTS OF OXIDATIVE STRESS ON THE RETINAL GANGLION CELLS. THESE EXPERIMENTS WILL IDENTIFY THE EARLY DEFICITS IN GANGLION CELL ELECTROPHYSIOLOGICAL FUNCTION RESULTING FROM MITOCHONDRIAL DYSFUNCTION. BY CAREFULLY ANALYZING THE EARLIEST SIGNS OF CHANGES TO PHOTORECEPTOR RESPONSE AND SYNAPTIC OUTPUT TO BIPOLAR CELLS, THIS DETECTION AND INTERPRETATION COULD LEAD TO DIAGNOSTIC CLUES THAT AID DETECTION OF PERSONS AT HIGHER RISK OF GLAUCOMA OR OPTIC NEUROPATHY. ANOTHER NEW AREA INVOLVES INVESTIGATIONS OF THE EARLY STAGES OF INFLAMMATION-MEDIATED DEGENERATION OF BLOOD VESSELS, FOCUSING ON THE ATROPHY OF INNER RETINAL VESSELS IN DIABETIC RETINOPATHY AND THE OUTER RETINAL BLOOD SUPPLY FROM THE CHORIOCAPILLARIS/CHOROID IN AGE-RELATED MACULAR DEGENERATION. THIS INTEGRATION OF THE PRINCIPLES OF DIABETES, RETINAL INFLAMMATION, AND VASCULAR MECHANOBIOLOGY, HAS LED TO A UNIQUE INTERDISCIPLINARY APPROACH THAT HAS THE POTENTIAL TO IDENTIFY OTHER PREVIOUSLY UNRECOGNIZED MECHANOCHEMICAL MECHANISMS UNDERLYING THE PATHOGENESIS OF THESE PREVALENT OCULAR DISEASES.


Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.

Outside Vendors & Contractors

Vendor Name (Service)Compensation
Crosbie Gliner Schiffman Southard
Legal
$101,815
Maginnis Knechtel And Mcintyre Llp
Audit And Tax
$121,000
Isaacson Miller Inc
Recruiting
$108,588
View All Vendors

Financial Statements

Statement of Revenue
Federated campaigns$0
Membership dues$0
Fundraising events$0
Related organizations$0
Government grants $1,765,208
All other contributions, gifts, grants, and similar amounts not included above$1,813,727
Noncash contributions included in lines 1a–1f $0
Total Revenue from Contributions, Gifts, Grants & Similar$3,578,935
Total Program Service Revenue$5,183,210
Investment income $1,128,467
Tax Exempt Bond Proceeds $0
Royalties $3,469
Net Rental Income $159,623
Net Gain/Loss on Asset Sales $56,047,249
Net Income from Fundraising Events $0
Net Income from Gaming Activities $0
Net Income from Sales of Inventory $0
Miscellaneous Revenue$0
Total Revenue $66,100,953

Grants Recieved

Over the last fiscal year, we have identified 6 grants that Doheny Eye Institute has recieved totaling $140,400.

Awarding OrganizationAmount
Morgan Stanley Global Impact Funding Trust Inc

Indianapolis, IN

PURPOSE: UNRESTRICTED GENERAL SUPPORT

$100,000
American Endowment Foundation

Hudson, OH

PURPOSE: SCIENCE

$25,000
Schwab Charitable Fund

San Francisco, CA

PURPOSE: HEALTH

$11,750
Augustyn Foundation Trust

Claremont, CA

PURPOSE: SUPPORT OF PUBLIC CHARITY

$2,000
Crary Foundation

Corona Del Mar, CA

PURPOSE: UNRESTRICTED

$1,500
John W Hancock Foundation

Long Beach, CA

PURPOSE: SUPPORT

$150
View Grant Recipient Profile

Endowment Analysis

Beg. Balance$42,699,406
Earnings-$6,980,970
Net Contributions$5,000
Other Expense$3,486,532
Ending Balance$32,236,904

Create an account to unlock the data you need.

or